PerspectiveCANCER

Potential of the Synthetic Lethality Principle

Science  15 Nov 2013:
Vol. 342, Issue 6160, pp. 809-811
DOI: 10.1126/science.1244669

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Summary

Most cancer mutations, including those causing a loss of function, are not directly “druggable” with conventional small-molecule drugs or biologicals, such as antibodies. Thus, despite our growing knowledge of mutations that drive cancer progression, there remains a frustrating gap in translating this information into the development of targeted treatments that kill only cancer cells. An approach that exploits a concept from genetics called “synthetic lethality” could provide a solution. But it has been over 15 years since that framework was proposed (1). Does the synthetic lethality principle still have the potential for treating cancer?